

## Bundled Payments for Care Improvement (BPCI) Advanced Annual Check-in Questionnaire

[illegible]

1

1

### Purpose:

Participants' activities and barriers related to designing and implementing the BPCI Advanced Model



### Instructions:


[illegible]

Diagram illustrating the location of the *rDNA* and *rD* genes on the *E. coli* chromosome. The *rDNA* gene is located at approximately 100 minutes, and the *rD* gene is located at approximately 110 minutes. The *rDNA* gene is transcribed into rRNA, and the *rD* gene is transcribed into 16S and 23S rRNA.

-

The following information is being provided to you for your information only. It is not intended to be used as a basis for any legal action or to create any legal obligation. It is provided for your information only.

- The following information is being provided to you for your information only. It is not intended to be used as a basis for any legal action or to create any legal obligation. It is provided for your information only.
- The following information is being provided to you for your information only. It is not intended to be used as a basis for any legal action or to create any legal obligation. It is provided for your information only.
- The following information is being provided to you for your information only. It is not intended to be used as a basis for any legal action or to create any legal obligation. It is provided for your information only.



The following information is being provided to you for your information only. It is not intended to be used as a basis for any legal action or to create any legal obligation. It is provided for your information only.

The following information is being provided to you for your information only. It is not intended to be used as a basis for any legal action or to create any legal obligation. It is provided for your information only.

## Contact:

The following information is being provided to you for your information only. It is not intended to be used as a basis for any legal action or to create any legal obligation. It is provided for your information only.

1003

☐  
☐  
☐  
☐  
☐

☐  
☐  
☐  
☐

1

□ □ □ □

□ □ □ □ □

□ □ □ □ □

100

## Participant Profile

9

1001

## Care Redesign Plan

1001

□ r □ □ □ □ □ D □ □ □ □ r □ □ □

☐

☐

☐

□ □ □ □ □ □ □ □ □ □ □ □ □ □

**D** **r** **d** **d** **R**

☐  
☐  
☐  
☐  
☐

[illegible][illegible]

## CEHRT Use

1. *To meet this criterion, at least 75 percent of eligible clinicians in each participating APM Entity group, or each hospital if hospitals are the APM Entities, to use CEHRT to document and communicate clinical care.*



☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ r ☐ ☐ ☐ ☐ ☐ ☐ d ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ E R ☐ ☐ ☐ ☐ r ☐ ☐ ☐ ☐ ☐

☐

☐

☐

1.  $\frac{1}{2} \frac{d}{dt} \left( \frac{1}{2} m v^2 \right) = \frac{1}{2} m v \frac{dv}{dt}$   
 $\frac{1}{2} m v \frac{dv}{dt} = \frac{1}{2} m v \frac{dv}{dt}$

□ □ □ □ □ □ □ □ □ □ □ □ □

## Partner Agreements

1. **Definition:** A **Decision Tree** is a model for classification and regression tasks. It consists of a root node, internal nodes, and leaf nodes. The root node branches into internal nodes, which further branch into leaf nodes. The leaf nodes represent the final classification or regression output.

□ □ □ □ □

□□□ □□□□□□□□ r□□□□□□□□□□□□□□□□□□□ d□□□ r□□□ □□□□□□ □□□□□□□□□□ r□□□□□□□□□□ r□□□□□□□□□□ r□□□

☐

☐

☐

☐

☐

[illegible]

☐☐☐☐☐

[illegible]

- [illegible]

4.

[illegible]

Diagram illustrating the structure of a DNA sequence. The sequence is represented by a horizontal bar divided into segments. The segments are labeled with letters: D, r, d, r. The segments are color-coded: D is blue, r is green, d is red, and r is green. The segments are arranged in a sequence: D, r, d, r. The segments are connected by lines, indicating a continuous sequence.

- □ □ □

[illegible]

115

□ □ □ □ □ □ □ □ □ □ □ □

☐  
☐  
☐  
☐  
☐



□□□□ □□□□ d □□ r □□□□□□□□ d r □□□□□□□□□□ r □ d the Participant's d □□□□□□□□□□  
□ □□□□□□□□□□□□□□□ r □□ r □□ rd □□□□□□□□□□□□□□□□ rr □□□□ □□□□□□

- □ □ □ □ □ □ □ □ □ □ □ □ □ □

### Internal Cost Savings (ICS)

**D**rdrdrrdd  
ddddd  
**d**

- □ □

☐ If selected 'Yes' to question 1, has the Participant \_\_\_\_\_d \_\_\_\_\_r \_\_\_\_\_d  
\_\_\_\_\_r \_\_\_\_\_r \_\_\_\_\_d \_\_\_\_\_d \_\_\_\_\_d \_\_\_\_\_d \_\_\_\_\_d

- 

### Net Payment Reconciliation Amount (NPRA)

**D** **r** **R** **d** **d** **r**

**r** **r** **d** **d** [Performance Period 1: October 1, 2018 through June 30, 2019]

- □ □ □ □ □

- 

[illegible]

## Compliance Plan

1. ☐ If your response is ‘yes’, please upload this document to the amendment section of the [Participant Portal](#). If your Compliance Plan includes multiple appendices, you can upload the main document only.]  
☐  
☐  
☐  
☐  
☐

## Waivers (Fraud & Abuse Waivers and Medicare Payment Policy Waivers)

Participant Profile Selection Does Not Limit Use of Waivers”

[illegible]

□ □ □

[illegible]

☐

☐

☐

[illegible]

-  

[illegible]

1001

[illegible]

333

[illegible]

☐

☐

☐

☐

☐

[illegible]

☐  
☐  
☐  
☐  
☐  
☐

[illegible]

-   
  


1000000

[illegible]

1000000

[illegible][illegible]

□ □ □

☐ If selected 'Other' to question

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □

□ □ □ □ □

9

□ □ □ □

[illegible]

1





[illegible]

## BPCI Advanced Impact



1





☐ If selected 'Yes' to either question 1 or 2, ☐ **d** ☐ **r** ☐



5



1

☐

1



7

☐☐  
☐☐☐

[illegible]

□ □ □ □ □ □ □ □ □ □ □ □ □



5







5

[illegible]

d

[illegible]

□ □ □ □ □ **R** □ □ □ □ □

□ □ □ r □



## Document Submission



□

$\frac{1}{n} \sum_{i=1}^n \left( \frac{1}{m_i} \sum_{j=1}^{m_i} x_{ij} \right) = \frac{1}{n} \sum_{i=1}^n \bar{x}_i$



5

☐

9

1

5

☐☐  
☐

1

111



[illegible]

- ☐

☐

☐

☐

☐

## Self-disclosed Investigations or Sanctions




[illegible]

- 

2. I selected 'Yes' to the question "Do you agree to participate in the study?"
- I understand that my participation in the study is voluntary and that I may withdraw from the study at any time without penalty or loss of benefits to which I am entitled.
- Additional information is located under Article 13 of the [Participation Agreement](#).

- □ □ □ □ □

### Other Issues Not Previously Listed

-